Two phase 3 clinical trials of KPI-121 0.25% for dry eye disease showed mixed results, according to a press release from Kala Pharmaceuticals.
The STRIDE 1 trial showed statistical significance for its primary sign endpoint of conjunctival hyperemia change from baseline to day 15 and its primary symptom endpoint of ocular discomfort severity change from baseline to day 15, the release said.
Also in STRIDE 1, a secondary prespecified primary symptom endpoint of ocular discomfort severity change from baseline to day 15 was met, but a secondary prespecified primary sign (Read more...)
Uncategorized